# NYU Langone Health

> NYU Langone Health is a VC fund in New York backing Biotechnology and Medical. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 3
- Last investment: Jan 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nyulangonehealth
- X (Twitter): https://twitter.com/nyulangone
- Website: https://nyulangone.org/
- Facebook: https://www.facebook.com/NYULangone/?fref=ts

NYU Langone Health is a nonprofit organization that provides a center of excellence in healthcare, research, and medical education.

## Contacts

5 contacts available for NYU Langone Health. Shizune tracks 13 team members at NYU Langone Health. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nyu-langone-health?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Product Research | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alan G. Harris | Adjunct Professor of Medicine | 0 | — |
| Joseph J. Greco | SVP, Chief of Hospital Operations NYU Winthrop | 0 | — |
| Adi Mashiach | Guest Lecturer | 0 | — |
| Alison Bateman-House | Chair, Compassionate Use Advisory Committee (CompAC) Infectious Diseases (ID) | 0 | — |
| A Reza Radjabi | Private Attending | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aethon Therapeutics | Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations. | $30M | Series A | Jan 09, 2023 |  |
| Aethon Therapeutics | Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations. | $30M | Series A | Jan 09, 2023 |  |
| Ajax Therapeutics | Ajax Therapeutics develops targeted therapies for hematologic cancers, with a focus on treating myeloproliferative neoplasms through precision drug discovery approaches. The company applies computational chemistry and structural biology to design small-molecule therapies that selectively target disease-driving proteins while minimizing off-targeteffects. Its research centers on next-generation inhibitors of the JAK2 protein, a key driver of certain blood cancers, using a differentiated mechanism that binds the Type II conformation of the kinase. This approach aims to improve treatment effectiveness and address limitations of existing therapies that provide symptom relief but do not fully suppress disease progression. It integrates discovery, preclinical research, and clinical development within its operating model, enabling continuous refinement of drug candidates based on biological insights and trial data. It collaborates with research institutions and leverages scientific expertise in oncology and molecular medicine to support development efforts. | $40M | Venture - Series Unknown | Jun 01, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Apple Tree Partners](https://shizune.co/investors/profile/apple-tree-partners) — VC Fund, 6 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 1 deal together
- Inning One Ventures — VC Fund, 1 deal together
- Memorial Sloan - Kettering Cancer Center — VC Fund, 1 deal together
- Schrödinger — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does NYU Langone Health invest in?

NYU Langone Health invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NYU Langone Health?

Public channels for NYU Langone Health include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NYU Langone Health?

The team at NYU Langone Health includes Alan G. Harris (Adjunct Professor of Medicine), Joseph J. Greco (SVP, Chief of Hospital Operations NYU Winthrop) and Adi Mashiach (Guest Lecturer), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co